dr. papadimitrakopoulou on distinguishing features of the guardant360 assay in lung cancer
Published 5 years ago • 192 plays • Length 0:50Download video MP4
Download video MP3
Similar videos
-
1:31
dr. papadimitrakopoulou on importance of more targeted therapies in nsclc
-
0:56
dr. papadimitrakopoulou on role of immunotherapy in lung cancer
-
1:53
dr. papadimitrakopoulou on immunotherapy combinations in lung cancer
-
1:30
dr. papadimitrakopoulou on impactful targeted therapies in lung cancer
-
0:53
dr. papadimitrakopoulou on benefits of liquid biopsy versus standard tissue in lung cancer
-
1:51
dr. papadimitrakopoulou on biomarker-driven clinical trials in nsclc
-
1:00
dr. papadimitrakopoulou provides an update on pembrolizumab for lung cancer
-
2:36
dr. papadimitrakopoulou discusses the lung-map trial
-
1:48
dr. papadimitrakopoulou on the utility of liquid biopsies in nsclc
-
1:00
dr. papadimitrakopoulou on adverse events associated with immunotherapy in lung cancer
-
3:22
liquid biopsy for identifying genomic targets in metastatic nsclc | vassiliki papadimitrakopoulou
-
1:32
dr. papadimitrakopoulou on implications of the nile trial in nsclc
-
1:14
dr. lopategui on the use of liquid biopsies in lung cancer
-
4:06
lung cancer patient cases – where the guardant360® test was used
-
0:24
guardant360’s comprehensive genotyping in nsclc
-
3:17
clariifi - liquid biopsy and guardant 360
-
2:12
prof. cho byoung chul shares his experience of using the guardant360® test in his clinic
-
6:53
guardant360® conference videos
-
0:22
85.7 percent had objective tumor response after guardant360® test